Identification of new pancreatic beta cell targets for In vivo imaging by a systems biology approach

Current Pharmaceutical Design

Volumn 16, Issue 14, 2010, Pages 1609-1618

  Bouckenooghe, Thomas ^a   Flamez, Daisy ^a   Ortis, Fernanda ^a   Goldman, Serge ^b   Eizirik, Decio L ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Beta cell imaging; Beta cell mass; Diabetes mellitus; Pancreatic beta cells; System biology

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL LOSS; CHRONIC PANCREATITIS; DIABETES MELLITUS; DNA MICROARRAY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; IMAGING; IN VIVO IMAGING; IN VIVO STUDY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMS BIOLOGY; CYTOLOGY; PANCREAS ISLET; REVIEW; SCINTISCANNING;

BIOLOGICAL MARKERS; HUMANS; ISLETS OF LANGERHANS; POSITRON-EMISSION TOMOGRAPHY; SYSTEMS BIOLOGY;

EID: 77956199503     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791164117     Document Type: Article

References (119)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
2. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 2002; 18 (Suppl 3): S3-8.
3. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-33.
4. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54 (Suppl 2): S97-107.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10.
6. Klinke DJ. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008; 3: e1374.
7. Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA. Noninvasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 2004; 6: 652-9.
8. Robertson RP. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 2007; 56: 2420-4.
9. Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, Uhl W, et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009; 58: 1595-603.
10. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51: 2148-57.
11. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5: 219-26.
12. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signaltransduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-33.
13. Strandell E, Eizirik DL, Sandler S. Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 1990; 85: 1944-50.
14. Strandell E, Sandler S, Boitard C, Eizirik DL. Role of infiltrating T cells for impaired glucose metabolism in pancreatic islets isolated from non-obese diabetic mice. Diabetologia 1992; 35: 924-31.
15. Marchetti P, Dotta F, Ling Z, Lupi R, Del Guerra S, Santangelo C, et al. Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care 2000; 23: 701-3.
16. Gardner SF, Green JA, Bednarczyk EM, Farnett L, Miraldi F. Principles and clinical applications of positron emission tomography. Am J Hosp Pharm 1992; 49: 1499-506.
17. Sands MJ, Levitin A. Basics of magnetic resonance imaging. Semin Vasc Surg 2004; 17: 66-82.
18. Moser E, Stadlbauer A, Windischberger C, Quick HH, Ladd ME. Magnetic resonance imaging methodology. Eur J Nucl Med Mol Imaging 2009; 36 (Suppl 1): S30-S41.
19. Evgenov NV, Medarova Z, Pratt J, Pantazopoulos P, Leyting S, Bonner-Weir S, et al. In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes 2006; 55: 2419-28.
20. Medarova Z, Vallabhajosyula P, Tena A, Evgenov N, Pantazopoulos P, Tchipashvili V, et al. In vivo imaging of autologous islet grafts in the liver and under the kidney capsule in non-human primates. Transplantation 2009; 87: 1659-66.
21. Marzola P, Longoni B, Szilagyi E, Merigo F, Nicolato E, Fiorini S, et al. In vivo visualization of transplanted pancreatic islets by MRI: comparison between in vivo, histological and electron microscopy findings. Contrast Media Mol Imaging 2009; 4: 135-42.
22. Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci USA 2004; 101: 12634-9.
23. Turvey SE, Swart E, Denis MC, Mahmood U, Benoist C, Weissleder R, et al. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest 2005; 115: 2454-61.
24. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008; 36: 343-7.
25. Antkowiak PF, Tersey SA, Carter JD, Vandsburger MH, Nadler JL, Epstein FH, et al. Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging. Am J Physiol Endocrinol Metab 2009; 296: E573-E578.
26. Moore A, Bonner-Weir S, Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes 2001; 50: 2231-6.
27. Aaen K, Rygaard J, Josefsen K, Petersen H, Brogren CH, Horn T, et al. Dependence of antigen expression on functional state of betacells. Diabetes 1990; 39: 697-701.
28. Brogren CH, Hirsch F, Wood P, Druet P, Poussier P. Production and characterization of a monoclonal islet cell surface autoantibody from the BB rat. Diabetologia 1986; 29: 330-3.
29. Buschard K, Brogren CH, Ropke C, Rygaard J. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2. APMIS 1988; 96: 342-6.
30. Hampe CS, Wallen AR, Schlosser M, Ziegler M, Sweet IR. Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass. Exp Clin Endocrinol Diabetes 2005; 113: 381-7.
31. Lu Y, Dang H, Middleton B, Zhang Z, Washburn L, Stout DB, et al. Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad Sci USA 2006; 103: 11294-9.
32. Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, et al. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther 2005; 12: 329-39.
33. Malaisse WJ, Ladriere L, Cancelas J, Acitores A, Villanueva-Penacarrillo ML, Valverde I. Pancreatic and hepatic glycogen content in normoglycemic and hyperglycemic rats. Mol Cell Biochem 2001; 219: 45-9.
34. Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Wallen AR, Marcum ES, et al. Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun 2004; 314: 976-83.
35. Crenier L, Courtois P, Malaisse WJ. Uptake of tritiated Dmannoheptulose by liver, pancreatic exocrine and endocrine cells. Int J Mol Med 2001; 8: 155-7.
36. Schneider S, Feilen PJ, Schreckenberger M, Schwanstecher M, Schwanstecher C, Buchholz HG, et al. In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the noninvasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes 2005; 113: 388-95.
37. Schneider S, Ueberberg S, Korobeynikov A, Schechinger W, Schwanstecher C, Schwanstecher M, et al. Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul Pept 2007; 139: 122-7.
38. Weihe E, Schafer MK, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci 1994; 5: 149-64.
39. Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003; 51: 1027-40.
40. Maffei A, Liu Z, Witkowski P, Moschella F, Del Pozzo G, Liu E, et al. Identification of tissue-restricted transcripts in human islets. Endocrinology 2004; 145: 4513-21.
41. Saisho Y, Harris PE, Butler AE, Galasso R, Gurlo T, Rizza RA, et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 2008; 39: 543-51.
42. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol 2006; 33: 855-64.
43. Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, et al. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)- DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 2008; 49: 1171-6.
44. Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. VMAT2 gene expression and function as it applies to imaging betacell mass. J Mol Med 2008; 86: 5-16.
45. Murthy R, Harris P, Simpson N, Van Heertum R, Leibel R, Mann JJ, et al. Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates. Eur J Nucl Med Mol Imaging 2008; 35: 790-7.
46. Freeby M, Goland R, Ichise M, Maffei A, Leibel R, Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab 2008; 10 (Suppl 4): 98-108.
47. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, et al. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009; 50: 382-9.
48. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001; 2: 343-72.
49. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger DA, Yaffe MB. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005; 310: 1646-53.
50. Eizirik DL, Moore F, Flamez D, Ortis F. Use of a systems biology approach to understand pancreatic beta-cell death in Type 1 diabetes. Biochem Soc Trans 2008; 36: 321-7.
51. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, III, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-6.
52. Dufva M. Introduction to microarray technology. Methods Mol Biol 2009; 529: 1-22.
53. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-44.
54. White KP. Functional genomics and the study of development, variation and evolution. Nat Rev Genet 2001; 2: 528-37.
55. Rifkin SA, Kim J, White KP. Evolution of gene expression in the Drosophila melanogaster subgroup. Nat Genet 2003; 33: 138-44.
56. Passador-Gurgel G, Hsieh WP, Hunt P, Deighton N, Gibson G. Quantitative trait transcripts for nicotine resistance in Drosophila melanogaster. Nat Genet 2007; 39: 264-8.
57. Xing Y, Kapur K, Wong WH. Probe selection and expression index computation of Affymetrix Exon Arrays. PLoS One 2006; 1: e88.
58. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-15.
59. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006; 7: 55-65.
60. Gaidatzis D, Jacobeit K, Oakeley EJ, Stadler MB. Overestimation of alternative splicing caused by variable probe characteristics in exon arrays. Nucleic Acids Res 2009; 37(16): e107.
61. Reinartz J, Bruyns E, Lin JZ, Burcham T, Brenner S, Bowen B, et al. Massively parallel signature sequencing (MPSS) as a tool for indepth quantitative gene expression profiling in all organisms. Brief Funct Genomic Proteomic 2002; 1: 95-104.
62. Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, Khrebtukova I, et al. An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res 2005; 15: 1007-14.
63. Shendure J. The beginning of the end for microarrays? Nat Methods 2008; 5: 585-7.
64. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437: 376-80.
65. Bennett ST, Barnes C, Cox A, Davies L, Brown C. Toward the 1,000 dollars human genome. Pharmacogenomics 2005; 6: 373-82.
66. Korbel JO, Urban AE, Affourtit JP, Godwin B, Grubert F, Simons JF, et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 2007; 318: 420-6.
67. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-45.
68. Mikkelsen TS, Wakefield MJ, Aken B, Amemiya CT, Chang JL, Duke S, et al. Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences. Nature 2007; 447: 167-77.
69. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 2008; 452: 215-9.
70. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008; 321: 956-60.
71. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 2008; 18: 1509-17.
72. Lister R, Gregory BD, Ecker JR. Next is now: new technologies for sequencing of genomes, transcriptomes, and beyond. Curr Opin Plant Biol 2009; 12: 107-18.
73. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9: 387-402.
74. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by highthroughput sequencing. Nat Genet 2008.
75. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-11.
76. Bhasi A, Philip P, Sreedharan VT, Senapathy P. AspAlt: a tool for inter-database, inter-genomic and user-specific comparative analysis of alternative transcription and alternative splicing in 46 eukaryotes. Genomics 2009; 94: 48-54.
77. Rogers S, Girolami M, Kolch W, Waters KM, Liu T, Thrall B, et al. Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics 2008; 24: 2894-900.
78. D'Hertog W, Mathieu C, Overbergh L. Type 1 diabetes: entering the proteomic era. Expert Rev Proteomics 2006; 3: 223-36.
79. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006; 312: 212-7.
80. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207.
81. Rabilloud T. Membrane proteins and proteomics: love is possible, but so difficult. Electrophoresis 2009; 30 (Suppl 1): S174-S180.
82. D'Hertog W, Overbergh L, Lage K, Ferreira GB, Maris M, Gysemans C, et al. Proteomics analysis of cytokine-induced dysfunction and death in insulin-producing INS-1E cells: new insights into the pathways involved. Mol Cell Proteomics 2007; 6: 2180-99.
83. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29: 42-61.
84. Gurzov EN, Ortis F, Cunha DA, Gosset G, Li M, Cardozo AK, et al. Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis. Cell Death Differ 2009; 16(11): 1539-50.
85. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3: 317-25.
86. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3: 2085-90.
87. Huang J, Zhu H, Haggarty SJ, Spring DR, Hwang H, Jin F, et al. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc Natl Acad Sci USA 2004; 101: 16594-9.
88. Flamez D, Roland I, Berton A, Kutlu B, Dufrane D, Beckers MC, et al. A genomic-based approach identifies FXYD2 as a pancreatic beta cell specific biomarker. Diabetologia 2010; in press.
89. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
90. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 2006; 66: 11194-206.
91. Lee WP, Tzou WS. Computational methods for discovering gene networks from expression data. Brief Bioinform 2009; 10: 408-23.
92. Hulbert EM, Smink LJ, Adlem EC, Allen JE, Burdick DB, Burren OS, et al. T1DBase: integration and presentation of complex data for type 1 diabetes research. Nucleic Acids Res 2007; 35: D742-D746.
93. Kutlu B, Burdick D, Baxter D, Rasschaert J, Flamez D, Eizirik DL, et al. Detailed transcriptome atlas of the pancreatic beta cell. BMC Med Genomics 2009; 2: 3.
94. Ylipaasto P, Kutlu B, Rasilainen S, Rasschaert J, Salmela K, Teerijoki H, et al. Global profiling of coxsackievirus- and cytokineinduced gene expression in human pancreatic islets. Diabetologia 2005; 48: 1510-22.
95. Cardozo AK, Kruhoffer M, Leeman R, Orntoft T, Eizirik DL. Identification of novel cytokine-induced genes in pancreatic betacells by high-density oligonucleotide arrays. Diabetes 2001; 50: 909-20.
96. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, Kruhoffer M, et al. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem 2001; 276: 48879-86.
97. Rasschaert J, Liu D, Kutlu B, Cardozo AK, Kruhoffer M, Orntoft TF, et al. Global profiling of double stranded RNA- and IFNgamma-induced genes in rat pancreatic beta cells. Diabetologia 2003; 46: 1641-57.
98. Kutlu B, Cardozo AK, Darville MI, Kruhoffer M, Magnusson N, Orntoft T, et al. Discovery of gene networks regulating cytokineinduced dysfunction and apoptosis in insulin-producing INS-1 cells. Diabetes 2003; 52: 2701-19.
99. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104: 17040-5.
100. Pavlovic D, Chen MC, Bouwens L, Eizirik DL, Pipeleers D. Contribution of ductal cells to cytokine responses by human pancreatic islets. Diabetes 1999; 48: 29-33.
101. Pipeleers DG, in't Veld PA, Van de WM, Maes E, Schuit FC, Gepts W. A new in vitro model for the study of pancreatic A and B cells. Endocrinology 1985; 117: 806-16.
102. Bouckenooghe T, Vandewalle B, Moerman E, Danze PM, Lukowiak B, Muharram G, et al. Expression of progenitor cell markers during expansion of sorted human pancreatic beta cells. Gene Expr 2005; 12: 83-98.
103. Meyer K, Irminger JC, Moss LG, de Vargas LM, Oberholzer J, Bosco D, et al. Sorting human beta-cells consequent to targeted expression of green fluorescent protein. Diabetes 1998; 47: 1974-7.
104. Banerjee M, Otonkoski T. A simple two-step protocol for the purification of human pancreatic beta cells. Diabetologia 2009; 52: 621-5.
105. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002; 3: 285-98.
106. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6: 386-98.
107. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell 2006; 126: 37-47.
108. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006; 7: 325.
109. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-6.
110. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-93.
111. Xu Q, Modrek B, Lee C. Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 2002; 30: 3754-66.
112. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003; 302: 2141-4.
113. Yeo G, Holste D, Kreiman G, Burge CB. Variation in alternative splicing across human tissues. Genome Biol 2004; 5: R74.
114. Ortis F, Naamane N, Flamez D, Ladrière L, Moore F, Cunha DA, et al. The cytokines IL-1beta and TNF-alpha regulate different transcriptional and alternative splicing networks in primary beta cells. Diabetes 2010; 59: 358-374.
115. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA 2003; 100: 189-92.
116. Ortis F, Cardozo AK, Crispim D, Storling J, Mandrup-Poulsen T, Eizirik DL. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol Endocrinol 2006; 20: 1867-79.
117. Abeywardena MY, Leifert WR, Warnes KE, Varghese JN, Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009; 15(15): 1809-21.
118. Myllyharju J. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr Pharm Des 2009; 15(33): 3878-85.
119. Traish AM, Abu-Zahra H, Guay AT. The brain, the penis and steroid hormones: clinical correlates with endothelial dysfunction. Curr Pharm Des 2008; 14(35): 3723-36.